financetom
Business
financetom
/
Business
/
Pluri Receives US Patent for Immune Cell Expansion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pluri Receives US Patent for Immune Cell Expansion
Apr 8, 2024 10:39 AM

01:16 PM EDT, 04/08/2024 (MT Newswires) -- Pluri ( PLUR ) said Monday it has received a new US patent for technology used in the expansion of immune cells.

The new patent addresses challenges in allogeneic cell therapies, including limited donor cell availability, the company said.

Price: 5.44, Change: +0.02, Percent Change: +0.37

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bank7 Acquires First American Mortgage
Bank7 Acquires First American Mortgage
Feb 28, 2025
01:49 PM EST, 02/28/2025 (MT Newswires) -- Bank7 ( BSVN ) revealed Friday the acquisition of First American Mortgage, a residential mortgage lending services provider. Financial details weren't disclosed. Bank7 ( BSVN ) shares were up 1% in recent trading. Price: 41.06, Change: +0.46, Percent Change: +1.13 ...
BMO Keeps Outperform on Kinaxis After Q4 Beat
BMO Keeps Outperform on Kinaxis After Q4 Beat
Feb 28, 2025
01:52 PM EST, 02/28/2025 (MT Newswires) -- BMO remains Outperform-rated on Kinaxis ( KXSCF ) following fourth-quarter results that beat consensus on SaaS revenue and EBITDA, while FY2025 guidance was a hair light on SaaS revenue and a hair above on EBITDA. Analyst Thanos Moschopoulos notes that Kinaxis ( KXSCF ) had a record quarter of new ARR bookings, a...
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
Feb 28, 2025
By Rishika Sadam MUMBAI, March 1 (Reuters) - India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said on Friday. The company is among many Indian drugmakers looking to grab a slice of the growing weight-loss drug market, which...
Laurentian Bank Keeps Underperform, C$27 Target at National Bank
Laurentian Bank Keeps Underperform, C$27 Target at National Bank
Feb 28, 2025
01:50 PM EST, 02/28/2025 (MT Newswires) -- Laurentian Bank (LB.TO) has kept an Underperform rating, C$27 Target at National Bank in National's updated Q1 2025 earnings commentary. LB reported Q1 2025 adjusted EPS of $0.78 versus a National Bank Financial forecast of $0.76 and consensus of $0.76. Among key takeaways, National said LB reported a good Q1 2025, highlighted by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved